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Abstract
Leukemia-initiating cells of core binding
factor (CBF) acute myeloid leukemia
(AML) likely derive from early committed
hematopoietic precursors expressing CD33.
As such, targeting CD33 could ameliorate
the chance of cure of CBF AML patients. We
compared 12 CBF AML patients treated with
Fludarabine, Cytarabine, Idarubicin and
Gemtuzumab Ozogamicin  (FLAI-GO
regimen) with 25 CBF AML patients treated
with the same schedule, but without GO.
With the limit of small numbers, we
observed a consistent trend toward better
overall survival, disease free survival and
event free survival in the FLAI-GO group.
We also demonstrated the ability of GO to
induce the disappearance in vitro of the
AML1-ETO molecular transcript in a
polymerase chain reaction-positive graft
without decreasing the clonogenic potential
of CD34+/CD38- cells. This represent the
proof of principle for using GO in a purging
strategy before autologous stem cell
transplantation. Therefore, our data argue in
favor of the reinstitution of GO in the
therapy of CBF AML.
Brief Report
Core Binding Factor (CBF) Acute
Myeloid Leukemia (AML) patients
experience treatment  failure in the order of
40-50%.1 As such, efforts have been made to
increase the dose  intensity of first line
treatment over the standard
Daunorubicin/Cytarabine 3+7 induction,
under the assumption that better survival
could be achieved by obtaining a deeper
early clearance of blasts before clonal
evolution of the disease. Among other
attempts, the addition of a third
chemotherapeutic drug, such as Fludarabine,
has been tested in various clinical trials,2,3
with conflicting results regarding Overall
Survival (OS), but, in most cases, with an
increase in the rate of complete remission
(CR) and Disease-Free Survival (DFS).2,3
Moreover, novel agents with compatible
safety profile have been tested in addition to
chemotherapy; among these, the
immunoconjugate Gemtuzumab
Ozogamicin (GO), which combines in a
single agent a monoclonal antibody targeting
CD33 with the DNA damaging toxin
calicheamicin. Following initial studies, GO
has been combined to chemotherapy to
improve efficacy, particularly in the case of
CBF AML, in which blasts highly express
the target antigen.1,3 Three-drug Fludarabine-
based regimens combined with GO proved
successful mainly in the setting of
cytogenetically favorable, such as CBF
AML, or intermediate-risk AML,3,4 whereas
results have somehow been disappointing in
adverse risk patients.3,4 Despite this, the
clinical development of GO has suffered
from concerns raised by an increased
incidence of hepatotoxicity and veno-
occlusive disease when GO was used at the
dose of 9 mg/m2 twice during induction,5
and from the early results of a randomized
phase-3 trial that showed no advantage in OS
and a significant increase of Treatment-
Related Mortality  (TRM) (5% vs 1%) in the
GO-treated group.6 This ultimately led to the
withdrawal of the drug from the market in
2010. Later studies3,7,8 showed, on the
opposite, an unequivocal survival benefit by
GO, even if mainly restricted to CBF AML,
at the lower schedule of 3 to 6 mg/m2,
without neither increased hepatotoxicity nor
higher TRM.3,7,8 This led to the revaluation
of GO, which, unfortunately, has not yet
resulted in the reinstitution of the drug to
clinical practice.5
In order to address the role of GO in the
treatment of CBF AML, we retrospectively
reviewed 12 CBF AML patients [t(8;21)
n=8; inv(16) n=4] treated from 2006 to 2009
with the FLAI-GO regimen (Fludarabine 30
mg/m2 on days1-5; Cytarabine 2 gr/m2 on
days1-5; Idarubicin 10  mg/m2 on days 1,3,5;
GO 3 mg/m2 on day 6),4 and consolidated
with two high-dose cytarabine (HiDAC)-
based cycles (overall dose 24 gr/m2/cycle).
We applied a regimen that was previously
described in an independent series of AML
patients.4 Patients with c-KIT tyrosine
kinase domain mutation at codon 816
(TKD816) at diagnosis (n=2) or with the
persistence of molecular transcript, assessed
by sequential polymerase chain reaction
(PCR), at the end of consolidation (n=5), i.e.
Minimal Residual Disease (MRD)-
positivity, were then consolidated with either
allogeneic or autologous hematopoietic stem
cell transplantation (HSCT) based on the
availability of a donor. We decided to further
intensify the treatment of KIT mutated
patients early on, based on initial studies
showing an adverse prognosis of these
patients as compared to KIT wild-type CBF
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AML.9 Conversely, the persistence of the
molecular transcript at the end of
consolidation was considered a predictor of
adverse prognosis based on previous
experiences,10,11 as well as our own
unpublished data.
We compared this group with 25 CBF
AML patients [t(8;21) n=13; inv(16) n=12]
treated according to the same criteria and
with the same schedule, but without GO, in
the years 2003-2006 and 2010-2013. The
two groups were comparable in all clinical
and laboratory features  (Table 1). In the
latter group, autologous HSCT was
performed in 5 patients because of MRD-
positivity, and allogeneic HSCT was
performed in 2 patients because of the lack
of cytogenetic response after induction
therapy.
Patients in the two groups reached a
comparable rate of CR after induction
(n=12/12 vs 22/25, P=0.540); no death in
induction was observed, and all patients
completed their therapeutic schedule. At
median follow-up of 69.2 months, 3 patients
in the FLAI-GO group relapsed at 8, 14 and
42 months after the achievement of CR; of
these, two out of three achieved second CR
following rescue therapy and underwent
allogeneic HSCT. Conversely, at median
DFS 14.7 months, 11 patients of the FLAI
group relapsed; among these, 7 out of 10
achieved second CR and were consolidated
with allogeneic HSCT.  
As shown in Figure 1, we observed a
consistent, yet non-statistical trend towards
better OS, DFS and, most importantly in
evaluating the efficacy of first line therapy,
Event Free Survival (EFS) in the FLAI-GO
group (5-yrs OS 69.4% vs 48.6%, P=0.202;
5-yrs DFS 54.7% vs 42.4%, P=0.327; 5-yrs
EFS 54.7% vs 36.9%, P=0.136; Figure 1).
Besides, patients tended to relapse later
when treated with FLAI-GO (median DFS:
unreached vs 14.7 months; Figure 1). We
believe these differences did not reach the
statistical significance mainly due to small
numbers. The achievement of MRD-
negativity (FLAI-GO=100% of the 4
patients analyzed; FLAI=63% of the 13
patient analyzed), assessed by PCR, was of
pivotal prognostic importance (P<0.001 for
either OS, DFS and EFS). 
The potential of GO in the treatment of
CBF AML is based on strong biological
bases: first of all, most t(8;21) AML blasts
do not express the transporter P-glycoprotein
(Pgp),12 i.e. the Multi-Drug Resistance 1
(MDR1) gene product, and this seems
related to a selective repression of the
promoter of MDR1 by AML1-ETO.13
Several studies have pointed out how GO
extrusion by Pgp affects clinical response.14
Moreover, CBF fusion transcripts promote
leukemogenesis  by inducing the initial
expansion of a preleukemic myeloid cell
compartment predisposed to secondary
mutations and characterized by CD33+ early
committed myeloid precursors incorporating
the AML1-ETO or CBFB-MYH11
transcripts.15 According to this model,
founding Leukemia-Initiating Cells of CBF
AML, differently from other types of AML,
would arise from these early committed
myeloid precursors rather than the more
immature Hematopoietic Stem Cells,15 and
therefore be more sensitive to GO therapy
because of their markedly higher expression
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Table 1. Baseline patient characteristics.
                                                                          FLAI5                     My-FLAI5                   P
Median age                                                                     41.3 (18-66)                      46.3 (29-67)                    0.2602
Sex                                                                                    12 M + 13 F                        6 M + 6 F                       0.909
Secondary acute myeloid leukemia                                    0                                          0                                 NA
Hepatomegaly                                                                          4                                          2                                 1.0
Splenomegaly                                                                           3                                          2                                 1.0
Sarcoma                                                                                    0                                          1                                 1.0
Hemoglobin gr/dL                                                          8.4 (4.2-11)                       8.5 (5-13.6)                     0.9100
White blood cells ×103/ L                                            19.0 (1.6-95)                   18.7 (4.5-45.5)                  0.9706
N ×103/ L                                                                      1.86 (0.33-6.35)               2.58 (0.45-11.36)                0.3680
Mo ×103/ L                                                                   0.95 (0.01-2.56)                0.58 (0.01-2.68)                 0.1330
Ly ×103/ L                                                                     2.67 (0.50-6.80)                2.86 (0.60-7.73)                 0.8016
Blasts ×103/ L                                                             10.9 (0.01-65.55)               11.6 (0.22-32.0)                 0.9074
Platelets ×103/ L                                                           60.66 (8-255)                    73.72 (6-531)                   0.7150
Elevated LDH                                                                          18                                        10                              0.638
DIC                                                                                              2                                          2                               0.305
Acute renal failure                                                                  0                                          1                               0.314
t(8;21)/inv(16)                                                                      13/12                                     8/4                              0.491
FLT3-ITD                                                                                    3                                          2                                 1.0
NPM1 mutated                                                                         0                                          0                                 NA
KIT TKD 816 mutated                                                               1                                          1                                 1.0
Packed BM (>80%)                                                               12                                         5                               0.717
Additional cytogenetic abnormalities              None: 14 pts; 1: 7 pts;         None: 4; 1: 5 pts;                 0.387
                                                                                       2: 3 pts; 3: 1 pts               2: 1 pts; 3: 2 pts                      
Figure 1. Survival by treatment with
Gemtuzumab Ozogamicin (GO). Patients
receiving FLAI-GO induction therapy
showed a consistent, yet nonstatistical,
trend towards better Overall Survival (OS),
Disease-Free Survival (DFS) and, most
importantly in determining the effect of
first line treatment, Event-Free Survival
(EFS), as compared to a group of patients
treated with FLAI. Numbers of the two
groups are showed as n; only patients
achieving complete remission after induc-
tion therapy were considered in determin-
ing DFS. Inclusion criteria and treatment
schedule was the same in the two groups
apart from the addition of GO at 3 mg/m2
to induction therapy at day 6 of the FLAI-
GO regimen.
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of CD33. The distinctive chemosensitivity
shown by CBF AML1 could also be
explained by these biological differences.15
As such, autologous HSCT could be
used to increase the dose intensity of first
line therapy in selected patients, improving
OS, as shown by some studies.16 Results are
best when MRD-negativity in the bone
marrow and in the products of leukapheresis
is obtained before transplantation.17
Recently, a 5-year EFS of 93% was reported
in a small series of CBF AML patients
undergoing autologous HSCT with a PCR-
negative graft, with the disappearance of
CBF transcripts after HSCT in 8 out of 10
previously MRD-positive patients.18
Nonetheless, in a previous series we
observed that clinical outcome of patients
could be improved also when autologous
HSCT had been performed with CD34+
grafts with persistent molecular transcripts.16
We explain this finding by the higher overall
dose-intensity achieved by first line
treatment by including autologous HSCT.
The achievement of MRD-negativity has
been related to a better prognosis by many
trials.19 Autologous HSCT, performed at the
end of first line treatment, might be
beneficial for selected CBF AML patients to
achieve the disappearance of MRD,
especially when performed using MRD-
negative Peripheral Blood Stem Cells
(PBSC).17 Monoclonal antibodies are thus
being tested to provide in vivo purging of
PBSC. This approach resembles the use of
Rituximab in the therapy of patients affected
by CD20+ lymphomas and undergoing
autologous HSCT. Concerns are there,
though, that treatment with GO might affect
hematopoietic reconstitution by reducing the
number of hematopoietic long-term
repopulating cells collected by
leukapheresis. 
We therefore evaluated the clonogenic
growth of PBSC collected at the end of
consolidation therapy from five patients with
CBF AML. Briefly, mononuclear cells were
cultured in RPMI medium in the presence or
absence of GO at a concentration of 5 µg/mL
for two hours, a previously in vitro dose
proved able to induce the near-complete
saturation of the CD33 antigen sites.20 Cells
were then collected, GO removed by
centrifugation, and cells reseeded in Petri
dishes containing semisolid MethoCult GF-
H4434 medium. The number of
Colony-Forming Units (CFU) was
determined after 14 days incubation. 
Using unsorted cells, we observed a
significant decrease in the number of CFU-
GEMM (clonal efficiency 0.000697 vs
0.01037, P=0.016), CFU-GM (0.002606 vs
0.004071, P=0.038) and BFU-E colonies
(0.003213 vs 0.004697, P=0.031) in the cells
exposed to GO. We then performed the same
experiments on samples from the same
PBSC units after the enrichment in
CD34+/CD38- cells by immunomagnetic
sorting. The efficacy of this sorting was
proved by either immunophenotypic analysis
and functional assays, which resulted in
significantly more numerous CFU-GEMM,
CFU-GM, BFU-E (data not shown). This
time, though, we did not observe a
significant decrease in the clonogenic
potential of CD34+/CD38- cells by the
exposure to GO (0.01518 vs 0.02631,
P=0.351), thus confirming the preservation
of more immature hematopoietic precursors.
Moreover, in one MRD-positive patient we
could observe the disappearance of the
AML1-ETO molecular transcript following
in vitro incubation with GO at a
concentration of 5 µg/mL for two hours
(Figure 2). 
Therefore, with the limit of small
numbers, the results that we report suggest
the possibility of using GO in a purging
strategy that would possibly act on residual
CBF AML cells without  affecting the
repopulating ability of PBSC. In order to
avoid the limitation of in vitro purging, GO
could be used in vivo before CD34+ cell
collection in MRD-positive patients.
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Figure 2. Disappearance of AML1-ETO molecular transcript following in vitro purging
of PBSC with Gemtuzumab Ozogamicin. Samples from PBSC collected from 5 patients
affected by CBF AML at the end of consolidation were cultured in the presence or
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the end of consolidation and in the PBSC, incubation with GO obtained the disappear-
ance of cells expressing AML1-ETO, as tested by either direct and nested PCR. Abelson
(ABL) amplification was used as internal control. TG: initials of the patient’s name; Ctrl-
/Ctrl+: negative and positive controls.
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